UA92638U - Method for preventing emergence of primary end points in patients with unstable angina with comorbid arterial hypertension - Google Patents

Method for preventing emergence of primary end points in patients with unstable angina with comorbid arterial hypertension

Info

Publication number
UA92638U
UA92638U UAU201403247U UAU201403247U UA92638U UA 92638 U UA92638 U UA 92638U UA U201403247 U UAU201403247 U UA U201403247U UA U201403247 U UAU201403247 U UA U201403247U UA 92638 U UA92638 U UA 92638U
Authority
UA
Ukraine
Prior art keywords
comorbid
patients
end points
unstable angina
arterial hypertension
Prior art date
Application number
UAU201403247U
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Елена Витальевна Денесюк
Виталий Иванович Денесюк
Юлия Юрьевна Шушковская
Алена Викторовна Плесна
Original Assignee
Винницкий Национальный Медицинский Университет Им. Н.И. Пирогова
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Винницкий Национальный Медицинский Университет Им. Н.И. Пирогова filed Critical Винницкий Национальный Медицинский Университет Им. Н.И. Пирогова
Priority to UAU201403247U priority Critical patent/UA92638U/en
Publication of UA92638U publication Critical patent/UA92638U/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A method for preventing the emergence of the primary end points in the patients with unstable angina with comorbid arterial hypertension consists in the use of Bisoprolol as beta-adrenoblocker at a daily dose of 5-10 mg, Perindopril as an inhibitor of angiotensin-converting enzyme at a daily dose of 5-10 mg, Atorvastatin as antisclerotic drug at a daily dose of 20 mg, and acetylsalicylic acid at a daily dose of 75 mg for two years.
UAU201403247U 2014-03-31 2014-03-31 Method for preventing emergence of primary end points in patients with unstable angina with comorbid arterial hypertension UA92638U (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
UAU201403247U UA92638U (en) 2014-03-31 2014-03-31 Method for preventing emergence of primary end points in patients with unstable angina with comorbid arterial hypertension

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
UAU201403247U UA92638U (en) 2014-03-31 2014-03-31 Method for preventing emergence of primary end points in patients with unstable angina with comorbid arterial hypertension

Publications (1)

Publication Number Publication Date
UA92638U true UA92638U (en) 2014-08-26

Family

ID=52682033

Family Applications (1)

Application Number Title Priority Date Filing Date
UAU201403247U UA92638U (en) 2014-03-31 2014-03-31 Method for preventing emergence of primary end points in patients with unstable angina with comorbid arterial hypertension

Country Status (1)

Country Link
UA (1) UA92638U (en)

Similar Documents

Publication Publication Date Title
MY191574A (en) Pharmaceutical compositions comprising meloxicam
MX2020009780A (en) Autotaxin inhibitor compounds.
MX2016010235A (en) Pharmaceutical composition comprising erythrocytes encapsulating a plp-dependent enzyme and its cofactor.
CY1121999T1 (en) PHARMACEUTICAL FORMS OF DARUNAVIR COMBINATION
HN2012000023A (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITARY DISEASES
MX2016002580A (en) Combination of an alk inhibitor and a cdk inhibitor for the treatment of cell proliferative diseases.
TR201901348T4 (en) Pyrrolidinone derivatives as metap-2 inhibitors.
EP3278803A4 (en) Solid pharmaceutical dosage form of parp inhibitor, and application of solid pharmaceutical dosage form of parp inhibitor
MX2016015261A (en) Allisartan isoproxil solid dispersion and pharmaceutical composition thereof.
PH12015502706B1 (en) Oral formulation for the treatment of cardiovascular diseases
EP3915565A3 (en) Xanthine oxidase inhibitor formulations
MX2021003230A (en) Pharmaceutical compositions comprising meloxicam.
MX2015007945A (en) Uses and methods for the treatment of liver diseases or conditions.
TN2011000214A1 (en) Combination of hsp90 and herceptin inhibitors
UA92638U (en) Method for preventing emergence of primary end points in patients with unstable angina with comorbid arterial hypertension
MX2013002503A (en) Combination of hdac inhibitors with thrombocytopenia drugs.
EA201991007A1 (en) SOLID PHARMACEUTICAL COMPOSITIONS BASED ON LURAZIDONE HYDROCHLORIDE FOR ORAL USE
EA201790772A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING BETA-BLOCKER AND INHIBITOR ANGIOTENZIN-CONVERTING ENZYME
PH12020500472A1 (en) Autotaxin inhibitor compounds
MX2012013052A (en) Association of xanthine oxidase inhibitors and statins and use thereof.
UA106905U (en) Pharmaceutical formulation
UA97716U (en) MEDICINE IN THE FORM OF SYRUP CONTAINING FENSPIRIDE HYDROCHLORIDE
UA83498U (en) Method for correcting calcium metabolism in patients with arterial hypertension combined with osteoarthrosis
UA76589U (en) Method for correction of vascular-platelet hemostasis in patients with moderate and mild hypertension against concomitant diabetes
UA88462U (en) Solid dosage form of drug with sedative and hypnotic effects